DMAA, NCQA Collaborate on Disease Management Clinical Measures
WASHINGTON, DC—The Disease Management Association of America (DMAA) and National Committee for Quality Assurance (NCQA) today announced a collaborative agreement to develop performance measures in clinical areas for disease management.
The collaboration will advance an important initiative DMAA launched in 2006 to establish consensus guidelines for evaluating clinical and financial outcomes of disease management programs. That initiative produced a comprehensive guidelines document DMAA formally released today, at its 8th Annual Disease Management Leadership Forum, in Denver.
NCQA was among various nationally recognized and respected quality and accreditation organizations that contributed comment and other support during the guidelines development process, which emphasized inclusiveness and transparency.
"DMAA is committed to establishing close working relationships with all stakeholders in the disease management and care coordination community, especially those with a strong focus on quality," DMAA Executive Director Tracey Moorhead said. "Certainly, NCQA's highly regarded accreditation programs and development processes have been an important part of the evolution of disease management. On behalf of our members, I am delighted to have this opportunity to further enhance the delivery of quality, coordinated health care programs."
"Millions of Americans live with chronic medical conditions. Disease management is a key part of a spectrum of care that can improve their health and the quality of their lives," said Esther Emard, NCQA's chief operating officer. "NCQA is delighted to have an opportunity to work with DMAA to advance a common agenda of measurement and reporting on the quality of these vital services."
The collaborative agreement with NCQA is the first of several DMAA hopes to forge in the second phase of its guidelines project, scheduled to begin in January 2007. In this new phase, DMAA will seek to work with quality and accreditation leaders to develop a full set of clinical measures, quality measures, productivity measures, and process and utilization measures. Other priority areas include development of disease-specific population selection criteria, further refinement of the initial guidelines, and collaboration to "test drive" different methodologies.
# # #